The Repurpose

The Broad Institute will be searching through Roche's catalog of more than 300 failed compounds to find new possible uses for those drugs, Fierce Biotech reports. "Presumably, those compounds passed initial safety tests, meaning that renewed development for a new use might not require as much lengthy (and expensive) study as a never-before-trialed drug," Fierce Biotech writes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

Knee-Deep in Biotechs

CRISPR Fight Flares

Over Again

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.